References
- Bleyer A, O’Leary M, Barr R, et al., editors. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000. NIH Pub N° 06-5767. Bethesda, MD: National Cancer Institute; 2006.
- Bleyer A, Viny A, Barr R. Cancer in 15- to 29-year-olds by primary site. Oncologist 2006;11:590–601.
- Jaglowski SM, Linden E, Termuhlen AM, et al. Lymphoma in adolescents and young adults. Semin Oncol 2009;36:381–418.
- Wood WA, Lee SJ. Malignant hematologis diseases in adolescents and young adults. Blood 2011;117:5803–5815.
- Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
- Oschlies I, Klapper W, Zimmermann M, et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Fankfurt-Munster) multicenter trial. Blood 2006;107:4047–4052.
- Sandlund JT, Downing JR, Crist WM. Non-Hodgkin's lymphoma in childhood. N Engl J Med 1996;334:1238–1248.
- Tai E, Pollack LA, Townsend J, et al. Differences in non-Hodgkin's lymphoma survival between young adults and children. Arch Pediatr Adolesc Med 2010;164:218–224.
- Fisher R, Gaynor E, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328: 1002–1006.
- Coiffier B, Lepage E, Brière J, et al. CHOP plus rituximab compared with CHOP chemotherapy in elderly patients with diffuse large B-cell lymphoma. A Groupe d’Etude des Lymphomes de l’Adulte study. N Engl J Med 2002;346:235–242.
- Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the Mabthera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
- The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med.1993;329:987–994.
- Cheson BD, Horning SJ, Coiffier B, et al. Report of an International Workshop to standardize response criteria for non Hodgkin's lymphomas. J Clin Oncol 1999;4:1244–1253.
- Rosolen A, Mussolin L, Bonvini P, et al. Non Hodgkin lymphoma in adolescents and young adults. Eur J Cancer Suppl 2007;5:217–225.
- Montoto S, Fitzgibbon J. Transformation of B-cell lymphoma. J Clin Oncol 2011;29:1827–1834.
- Burkhardt B, Oschlies I, Klapper W, et al. Non Hodgkin's lymphoma in adolescents: experience in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia 2011; 25:153–160.
- Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphoma: dissimilarities from lymphomas in adults. Semin Oncol 1980;7:332–339.
- Gerrard M, Waxman IM, Sposto R, et al. Outcome and pathological classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy. Blood 2013;121:278–285.
- Rieger M, Osterborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial group study. Ann Oncol 2011;22:664–670.
- Lisfeld J, Burkhardt B, Meinhardt A, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia: dose-escalation does not increase the response rate. Br J Haematol 2012;159(Suppl. 1): 3, Abstract 6.
- Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group Report. Leukemia 2013;27:1174–1177.